| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22024 |
| Drug | Enfortumab vedotin |
| Brand | Padcev® |
| Indication | As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor |
| Assessment Process | |
| Rapid review commissioned | 22/04/2022 |
| Rapid review completed | 18/05/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of enfortumab vedotin (Padcev®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 27/05/2022 |
| Pre-submission consultation with Applicant | 19/07/2022 |
| Full submission received from Applicant | 23/11/2022 |
| Preliminary review sent to Applicant | 16/03/2023 |
| NCPE assessment re-commenced | 17/04/2023 |
| Factual accuracy sent to Applicant | 21/06/2023 |
| NCPE assessment re-commenced | 28/06/2023 |
| NCPE assessment completed | 12/07/2023 |
| NCPE assessment outcome | The NCPE recommends that enfortumab vedotin (Padcev®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations December 2023.
